{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:46Z","timestamp":1791894226671,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,4,27]],"date-time":"2008-04-27T00:00:00Z","timestamp":1209254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p>\n                    <jats:bold>Summary.\u2002<\/jats:bold>\n                    Experience of recombinant activated factor VII (rFVIIa, NovoSeven\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ; Novo Nordisk A\/S, Bagsvaerd, Denmark) to control haemorrhage in non\u2010haemophilic children is limited. The object of this study was to examine the applicability and safety of rFVIIa amongst a group of non\u2010haemophilic paediatric subjects. Details of all non\u2010haemophilic children \u226416\u2003years receiving rFVIIa whose data were recorded in the investigational, internet\u2010based registry,\n                    <jats:italic>haemostasis.com<\/jats:italic>\n                    were analysed. A total of 265 children (mean age 7.7\u2003years) were treated with rFVIIa; the median dose administered was 78.4\u2003\u03bcg\u2003kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    body weight (range 9.0\u2013393.4) and the median total dose received 100.0\u2003\u03bcg\u2003kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    body weight (range 10.9\u20131341.2). Therapeutic areas included surgery (34.5%), coagulopathy (including thrombocytopenia; 29.0%), spontaneous bleeding (17.2%), trauma (8.4%) and intracranial haemorrhage (4.5%). Two patients experienced thromboembolic events following administration of rFVIIa. Thirty\u2010nine patients died on account of haemorrhage or complications relating to their underlying condition; neither the thromboembolic events nor the deaths were related to rFVIIa administration. Bleeding stopped in 118\/237 (49.8%), markedly decreased in 54\/237 (22.8%), decreased in 51\/237 (21.5%), remained unchanged in 13\/237 (5.5%) and increased in 1\/237 (0.4%) patients. These results suggest that rFVIIa is safe and widely applicable in children to control non\u2010haemophilic haemorrhage.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01746.x","type":"journal-article","created":{"date-parts":[[2008,4,28]],"date-time":"2008-04-28T00:05:10Z","timestamp":1209341110000},"page":"753-762","source":"Crossref","is-referenced-by-count":14,"title":["Applicability and safety of recombinant activated factor VII to control non\u2010haemophilic haemorrhage: investigational experience in 265 children"],"prefix":"10.1111","volume":"14","author":[{"given":"M.","family":"HERBERTSON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"KENET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90142-8"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00427.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.175"},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1160\/TH03-03-0168","article-title":"Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay","volume":"90","author":"Antovic JP","year":"2003","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_6_2","first-page":"3","article-title":"Recombinant factor VIIa (NovoSeven) as a hemostatic agent","volume":"1","author":"Hedner U","year":"2001","journal-title":"Bloodline Rev"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2223"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000159087.85970.38"},{"key":"e_1_2_8_9_2","first-page":"712","article-title":"Off\u2010label use of recombinant activated factor VII (NovoSeven\u00ae)","volume":"29","author":"Ratko TA","year":"2004","journal-title":"P&Ts"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-005-1004-5"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20144"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04286.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200406000-00008"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.11.020"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200301000-00021"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200309000-00013"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000047629.79538.82"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00784-X"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066604267783"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000123546.78900.67"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-2108-1"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2005.01429.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000047645.37970.AB"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615947"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.002"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.293"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-42589"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2005.09.012"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00925.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8461"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01203.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01746.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01746.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:01:47Z","timestamp":1697173307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01746.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01746.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01746.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}